[
  {
    "ts": null,
    "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
    "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
    "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757545741,
      "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
      "id": 136692857,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153211726/image_2153211726.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
      "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=4541f6f0a773366fef1dac89b7bffb14201881d420d8ae55820741eea1d5de58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757544604,
      "headline": "Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 136689563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=4541f6f0a773366fef1dac89b7bffb14201881d420d8ae55820741eea1d5de58"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f038975cda5db7971f1a25e1c93b1023f7b1e9f7b41eebf4007691a319f193b4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757522280,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136716043,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f038975cda5db7971f1a25e1c93b1023f7b1e9f7b41eebf4007691a319f193b4"
    }
  },
  {
    "ts": null,
    "headline": "US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche",
    "summary": "The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist",
    "url": "https://finnhub.io/api/news?id=f04991b805687df7d0e7b785ccb2b6ad4f8b03b3dcc2c010e8cba58620f9434c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757504040,
      "headline": "US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche",
      "id": 136688716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist",
      "url": "https://finnhub.io/api/news?id=f04991b805687df7d0e7b785ccb2b6ad4f8b03b3dcc2c010e8cba58620f9434c"
    }
  }
]